SALUTENSIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SALUTENSIN (SALUTENSIN).

How it works

Salutensin is a combination of two antihypertensive agents: hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption; and reserpine, a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine) from presynaptic nerve terminals by irreversibly blocking vesicular monoamine transporter (VMAT), leading to decreased peripheral vasoconstriction and heart rate.

What the body does with it

Metabolism	Hydroflumethiazide: not extensively metabolized, mainly excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces.
Excretion	Primarily renal (65-75% as unchanged drug); biliary/fecal (20-30%) with enterohepatic recirculation; minor metabolism via CYP3A4 to inactive metabolites.
Half-life	Terminal elimination half-life: 18-24 hours (mean 20 h); clinically, requires 5-7 days to reach steady state; prolonged in renal impairment (CrCl <30 mL/min: up to 40 h) and in elderly.
Protein binding	98% bound to albumin and α1-acid glycoprotein; binding is concentration-independent; altered in hypoalbuminemia.
Volume of Distribution	0.15-0.25 L/kg (approx. 10-18 L in 70 kg adult); indicates moderate tissue distribution; Vd increased in hypertension (0.3 L/kg) and decreased in heart failure.
Bioavailability	Oral: 85-95% due to extensive absorption and minimal first-pass metabolism; food delays absorption but does not reduce extent; IV and IM: 100%.
Onset of Action	Oral: 1-2 hours; IV: 15-30 minutes; IM: 30-60 minutes.
Duration of Action	Oral: 24-36 hours (allows once-daily dosing); IV: 18-24 hours; antihypertensive effect persists for up to 48 hours after last dose.

Classification & Brands

Dosing & administration

Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.

Dosage form	TABLET
Renal impairment	Contraindicated if GFR <30 mL/min. If GFR 30-50 mL/min, reduce dose to half tablet daily and monitor potassium; avoid if potassium >5.5 mmol/L.
Liver impairment	Contraindicated in Child-Pugh class C. In class A or B, use with caution; start at half tablet daily and monitor hepatic function.
Pediatric use	Not recommended for children under 18 years due to lack of safety data.
Geriatric use	Start at half tablet daily (25 mg spironolactone + 2.5 mg bendroflumethiazide). Monitor renal function, electrolytes, and blood pressure closely. Avoid if creatinine clearance <30 mL/min.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SALUTENSIN (SALUTENSIN).

Breastfeeding	Excreted into breast milk; M/P ratio not established. Potential for adverse effects in nursing infant (hypotension, bradycardia). Use with caution, monitor infant for signs of hypotension.
Teratogenic Risk	First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimesters: Risk of fetal hypotension, decreased placental perfusion, oligohydramnios, and neonatal renal dysfunction or failure. Avoid use in pregnancy unless no alternative.

Warnings & precautions

■ FDA Black Box Warning

Reserpine may cause mental depression. Therapy should be discontinued at the first sign of depression (e.g., despondency, early morning insomnia, loss of appetite, impotence). Depressive reactions are more common in patients with a history of depression.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to thiazides, reserpine, or sulfonamides; anuria or severe renal impairment; history of mental depression; active peptic ulcer; ulcerative colitis; pheochromocytoma; electroconvulsive therapy; concurrent MAO inhibitor therapy.

Clinical Precautions

Precautions

Electrolyte imbalance (hypokalemia, hyponatremia), hypotension, drowsiness/sedation, depression risk, exacerbation of peptic ulcer or ulcerative colitis, use caution in renal/hepatic impairment, and avoid abrupt discontinuation (reserpine may cause withdrawal syndrome).

Clinical Tips & Counseling

Drug interactions

Loading safety data…

SALUTENSIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for SALUTENSIN (SALUTENSIN).

How it works

What the body does with it

Metabolism	Hydroflumethiazide: not extensively metabolized, mainly excreted unchanged in urine. Reserpine: extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces.
Excretion	Primarily renal (65-75% as unchanged drug); biliary/fecal (20-30%) with enterohepatic recirculation; minor metabolism via CYP3A4 to inactive metabolites.
Half-life	Terminal elimination half-life: 18-24 hours (mean 20 h); clinically, requires 5-7 days to reach steady state; prolonged in renal impairment (CrCl <30 mL/min: up to 40 h) and in elderly.
Protein binding	98% bound to albumin and α1-acid glycoprotein; binding is concentration-independent; altered in hypoalbuminemia.
Volume of Distribution	0.15-0.25 L/kg (approx. 10-18 L in 70 kg adult); indicates moderate tissue distribution; Vd increased in hypertension (0.3 L/kg) and decreased in heart failure.
Bioavailability	Oral: 85-95% due to extensive absorption and minimal first-pass metabolism; food delays absorption but does not reduce extent; IV and IM: 100%.
Onset of Action	Oral: 1-2 hours; IV: 15-30 minutes; IM: 30-60 minutes.
Duration of Action	Oral: 24-36 hours (allows once-daily dosing); IV: 18-24 hours; antihypertensive effect persists for up to 48 hours after last dose.

Classification & Brands

Dosing & administration

Oral, 1 tablet (50 mg spironolactone + 5 mg bendroflumethiazide) once daily. Maximum 2 tablets per day.

Dosage form	TABLET
Renal impairment	Contraindicated if GFR <30 mL/min. If GFR 30-50 mL/min, reduce dose to half tablet daily and monitor potassium; avoid if potassium >5.5 mmol/L.
Liver impairment	Contraindicated in Child-Pugh class C. In class A or B, use with caution; start at half tablet daily and monitor hepatic function.
Pediatric use	Not recommended for children under 18 years due to lack of safety data.
Geriatric use	Start at half tablet daily (25 mg spironolactone + 2.5 mg bendroflumethiazide). Monitor renal function, electrolytes, and blood pressure closely. Avoid if creatinine clearance <30 mL/min.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for SALUTENSIN (SALUTENSIN).

Breastfeeding	Excreted into breast milk; M/P ratio not established. Potential for adverse effects in nursing infant (hypotension, bradycardia). Use with caution, monitor infant for signs of hypotension.
Teratogenic Risk	First trimester: Limited human data; based on animal studies, possible increased risk of congenital anomalies including cardiovascular and renal defects. Second and third trimesters: Risk of fetal hypotension, decreased placental perfusion, oligohydramnios, and neonatal renal dysfunction or failure. Avoid use in pregnancy unless no alternative.